2173 results about "Microbiological growth" patented technology

Disclosed are implantable or insertable medical devices that provide resistance to microbial growth on and in the environment of the device and resistance to microbial adhesion and biofilm formation on the device. In particular, the invention discloses implantable or insertable medical devices that comprise at least one biocompatible matrix polymer region, an antimicrobial agent for providing resistance to microbial growth and a microbial adhesion / biofilm synthesis inhibitor for inhibiting the attachment of microbes and the synthesis and accumulation of biofilm on the surface of the medical device. Also disclosed are methods of manufacturing such devices under conditions that substantially prevent preferential partitioning of any of said bioactive agents to a surface of the biocompatible matrix polymer and substantially prevent chemical modification of said bioactive agents.

The invention provides a non-naturally occurring microorganism comprising one or more gene disruptions, the one or more gene disruptions occurring in genes encoding an enzyme obligatory to coupling 1,4-butanediol production to growth of the microorganism when the gene disruption reduces an activity of the enzyme, whereby theone or more gene disruptions confers stable growth-coupled production of 1,4-butanediol onto the non-naturally occurring microorganism. The microorganism can further comprise a gene encoding an enzyme in a 1,4-butanediol (BDO) biosynthetic pathway. The invention additionally relates to methods of using microorganisms to produce BDO.

The present invention relates to a pharmaceutical composition comprising a pharmaceutical agent and a pharmaceutically acceptable carrier, which carrier comprises a protein, for example, human serum albumin and / or deferoxamine. The human serum albumin is present in an amount effective to reduce one or more side effects associated with administration of the pharmaceutical composition. The invention also provides methods for reducing one or more side effects of administration of the pharmaceutical composition, methods for inhibiting microbial growth and oxidation in the pharmaceutical composition, and methods for enhancing transport and binding of a pharmaceutical agent to a cell.

The invention provides a non-naturally occurring microorganism comprising one or more gene disruptions, the one or more gene disruptions occurring in genes encoding an enzyme obligatory to coupling 1,4-butanediol production to growth of the microorganism when the gene disruption reduces an activity of the enzyme, whereby the one or more gene disruptions confers stable growth-coupled production of 1,4-butanediol onto the non-naturally occurring microorganism. The microorganism can further comprise a gene encoding an enzyme in a 1,4-butanediol (BDO) biosynthetic pathway. The invention additionally relates to methods of using microorganisms to produce BDO.

A transdermal electrotransport drug delivery device having an anode, a cathode and a source of electrical power electrically connected to the anode and the cathode. At least one of the anode and the cathode includes an electrode and a reservoir comprised of a housing composed of a polymeric material and an aqueous medium in contact with the housing. The aqueous medium includes (i) a drug or an electrolyte salt or a mixture thereof, (ii) propylene glycol, and (iii) an antimicrobial agent in an amount sufficient to inhibit microbial growth in the aqueous medium. The propylene glycol prevents the antimicrobial agent from being adsorbed by other materials used in the construction of the delivery device. A process for preparing a transdermal electrotransport drug delivery device is also provided.

The invention relates to a composite probiotic bacterium microecological preparation and a preparation method thereof. The preparation is prepared by mixing 1.0 to 20 percent of composite microbial bacterium powder, 5.0 to 50 percent of composite oligosaccharide, 30 to 80 percent of auxiliary protective carrier and 0.1 to 0.2 percent of edible essence. The composite probiotic bacterium microecological preparation is prepared from a beneficial microbial preparation and a microbial growth-promoting factor, namely the oligosaccharide, through special combination and technological recombination. The composite probiotic bacterium microecological preparation has the advantages that beneficial active bacteria and the oligosaccharide promote each other, so that the composite probiotic bacterium microecological preparation has the advantages of obviously improving the microecological environment of the whole intestine and contributing to the digestion, preventing and treating intestine diseases, treating diarrhea, chronic diarrhea, diarrhea which can not be cured by antibiotic, constipation, dyspepsia and abdominal distension which are caused by intestine dysbacteriosis, recovering the intestine flora balance, protecting the liver, reinforcing the functions of detoxication and toxin expulsion of the liver, reinforcing the disease prevention and resistance such as the resistance of human body, and the like.

The present invention relates to oral care compositions which provide a means to deliver actives which are useful in the prevention, treatment and / or management of dental and related tissue conditions, including dental caries, dental cavities, microbial flora, tartar, periodontal and related gum disease. In addition, the present invention may be used in the healthy maintenance of teeth and gums. Further aspects of the present invention are related to the present compositions being useful to whiten teeth and otherwise favorably impact the cosmetic appeal of the teeth and gums of a subject or patient. A further aspect of the present invention is directed to the inclusion of effective amounts of colostrum in dental care compositions for the unexpectedly high efficacy such formulations provide in inhibiting, reducing or otherwise preventing microbial growth, dental caries, plaque, cavities and gum disease, including periodontal disease. The use of colustrum with other enzymes as otherwise described herein represents a particularly preferred embodiment for use in the present invention because of the unexpected antimicrobial activity exhibited by the enzyme combination.

Disposable absorbent articles comprising an absorbent material and a degradable thermoplastic polymer composition comprising an aliphatic polyester and an antimicrobial composition. The antimicrobial composition includes an antimicrobial component and an enhancer component. The aliphatic polyester and antimicrobial composition are formed into webs by melt extrusion, such as nonwovens and films, that are incorporated into disposable absorbent articles, such as disposable infant diapers, adult incontinence articles, feminine hygiene articles such as sanitary napkins, panty liners and tampons, personal care wipes and household wipes to provide odor control, control of microbial growth, and control of microbial toxin production.

A method of preserving formulations is provided. The method includes the step of including a derivatized cyclodextrin in a formulation capable of sustaining microbial growth. One embodiment of the formulation employs a sulfoalkyl ether cyclodextrin as a preservative and optionally as a solubilizing and complexing agent. A suitable cyclodextrin is the CAPTISOL” brand cyclodextrin (sulfobutyl ether R-cyclodextrin). Whether or not the formulation includes a conventional preservative, the formulation will remain preserved for at least a minimum predetermined period. Specific embodiments of the invention include a carrier, a derivatized cyclodextrin and optionally one or more active agents, one or more water activity-reducing agents, and / or one or more complexation-enhancing agents. The derivatized cyclodextrin reduces the water activity of the formulation. A liquid formulation can be lyophilized or otherwise dried to yield a solid formulation that is optionally reconstitutable.

A method for the detection of microorganisms in a sample comprising contacting said sample with a biosensor concentration module, allowing microorganisms to grow for a first period of time and detecting growth of discrete microorganisms as an indication of the presence of said microorganisms.

An alcohol based hand surgical scrub, which includes cationic anti-microbial agent preservatives, cationic polymer film-forming agents and a skin emollient, and provides a long term residual, anti-microbial “invisible glove” on the skin. The composition provides an immediate reduction in bacterial microbes. The polymer system creates an invisible film on the skin following solvent evaporation. This invisible film provides a lasting anti-microbial barrier on the skin which acts to prevent microbial growth.

The present invention provides antimicrobial coatings for coating substrate surfaces, particularly medical devices, for preventing bacterial adhesion and biofilm formation by inhibiting microbial growth and proliferation on the coating surface. The antimicrobial coatings are composed of a hydrogel and a bioactive agent including a substantially water-insoluble antimicrobial metallic material that is solubilized within the coating. Antimicrobial coating formulations for obtaining such coatings, and coating methods are also described.

The present invention provides novel microorganisms, compositions and methods of use thereof, for treating, inhibiting or preventing the developing of a plant pathogenic disease and for killing or inhibiting growth of a variety of pests or pathogens. Provided are compositions comprising a novel endophytic fungal organism effective to inhibit the growth of or kill pests and pathogenic microbes, including Ganoderma boninense. Invention compositions are especially useful in preventing and treating basal stem rot in the oil palm, and can be applied on or in the vicinity of the plant or used to sterilize the plant growth medium prior to or concurrent with plant growth therein. The disclosure further provides substantially purified polynucleotides and polypeptides encoded thereby, together with methods of using those products, for example for making transgenic organism.

Disclosed are formulations of gamma-hydroxybutyrate in an aqueous medium that are resistant to microbial growth. Also disclosed are formulations of gamma-hydroxybutyrate that are also resistant to the conversion into GBL. Disclosed are methods to treat sleep disorders, including narcolepsy, with these stable formulations of GHB. The present invention also provides methods to treat alcohol and opiate withdrawal, reduced levels of growth hormone, increased intracranial pressure, and physical pain in a patient.

Disclosed are formulations of gamma-hydroxybutyrate in an aqueous medium that are resistant to microbial growth. Also disclosed are formulations of gamma-hydroxybutyrate that are also resistant to the conversion into GBL. Disclosed are methods to treat sleep disorders, including narcolepsy, with these stable formulations of GHB. The present invention also provides methods to treat alcohol and opiate withdrawal, reduced levels of growth hormone, increased intracranial pressure, and physical pain in a patient.

The present invention provides compositions comprising a poorly water soluble pharmaceutical agent, a carrier protein, and an antimicrobial agent, wherein significant microbial growth is inhibited in the composition. The amount of the antimicrobial agent in the composition may be below the level that induces a toxicological effect or at a level where a potential side effect can be controlled or tolerated. Also provided are compositions comprising a poorly water soluble pharmaceutical agent, a carrier protein, a sugar, and optionally an antimicrobial agent. Methods of using the compositions are also provided.

This invention relates to a method for coating a medical device comprising the steps of applying to at least a portion of the surface of the medical device, a bactericidal coating layer, wherein the bactericidal coating layer comprises a bactericidal agent; and applying to at least a portion of the surface of the medical device, a bacteriostatic coating, wherein the bacteriostatic coating layer comprises a bacteriostatic agent wherein the combination of the bactericidal and bacteriostatic agents are in an effective concentration to inhibit growth of microbial organisms relative to an uncoated medical device. The two antimicrobial agents are used to develop a kit comprising these compositions in one container or in separate containers. The kit is used to coat or flush medical devices prior to or after implantation in a mammal.

The present invention relates to a pharmaceutical composition comprising a pharmaceutical agent and a pharmaceutically acceptable carrier, which carrier comprises a protein, for example, human serun albumin and / or deferoxamine. The human serum albumin is present in an amount effective to reduce one or more side effects associated with administration of the pharmaceutical composition. The invention also provides methods for reducing one or more side effects of administration of the pharmaceutical composition, methods for inhibiting microbial growth and oxidation in the pharrmaceutical composition, and methods for enhancing transport and binding of a pharmaceutical agent to a cell.

The present invention provides aqueous oral formulations containing sertraline, or a pharmaceutically acceptable salt thereof, and a sulfoalkyl ether cyclodextrin. The liquid formulations are pleasant tasting, convenient to use, and chemically and physically stable. The liquid formulations can be administered directly or diluted before administration. Unlike the commercially available ZOLOFT™ formulation, the liquid formulations herein do not precipitate upon dilution with water, fruit juices, sodas or other pharmaceutically acceptable oral liquid carriers. The sulfoalkyl ether cyclodextrin-containing formulation provides significant advantages over the marketed non-aqueous formulation and other cyclodextrin-containing formulations of sertraline. The formulation can be self-preserved against microbial growth. The SAE-CD-containing formulation of sertraline can be provided in liquid form or as a reconstitutable powder. Both ready-to-use and concentrated liquid formulations can be prepared. The formulation is available as a clear solution or a suspension.

Susceptibility of sessile microorganisms to antimicrobial agents is tested with a method comprising growing the microorganisms on a support to form a biofilm, contacting the biofilm with a metabolic substrate having a chromogenic and / or fluorogenic moiety to continue a base-line metabolic activity of the biofilm, contacting the biofilm with one or more antimicrobial agents, determining an experimental metabolic activity of the biofilm by measuring a signal from the metabolic substrate, and comparing the base-line metabolic activity with the experimental activity. The biofilm may be grown in a device comprising a plurality of wells, each well having a planar bottom and at least on wall, a plurality of supports comprising discs for growing the biofilm, each support disposed within a well perpendicular to the planar bottom, and at least one cover that fittably seals the top of each well.

The invention discloses a composite microorganism viable bacteria preparation, which contains pediococcus, yeast and bacillus with the total bacteria count of more than 1 billion per gram. The invention also discloses a method for preparing the composite microorganism viable bacteria preparation, which comprises the following steps: performing amplification liquid culture on various strains respectively according to a conventional method in the field; mixing the materials according to a required proportion; and performing solid fermentation, drying and pulverization to obtain the composite microorganism viable bacteria preparation. The invention also discloses application of the composite microorganism viable bacteria preparation in preparing an organic waste water purifying agent and an aquaculture water body purifying agent, a deodorizer, a degreasing agent or an agent for removing pipe blockages for the hygiene of a refuse tip, a public place, an agricultural product market or a kitchen, feed additives in poultry and animal husbandry or pet culture, and preparations for controlling agricultural microorganism diseases. The composite microorganism viable bacteria preparation can effectively decompose a large amount of putrescent organic matters, inhibit the growth of harmful microorganisms and eliminate peculiar smells, and has the characteristics of high ammonia nitrogen removal rate, no generation of residual sludge, effective deodorization, low cost and the like.

Compositions comprising a Labiatae herb extract and a hop extract containing beta acids and methods of using them to extend the color life and retard the growth of microorganisms in fresh meat, fish and poultry stored in an atmosphere that contains 20% or more oxygen.

Disclosed are formulations of gamma-hydroxybutyrate in an aqueous medium that are resistant to microbial growth. Also disclosed are formulations of gamma-hydroxybutyrate that are also resistant to the conversion into GBL. Disclosed are methods to treat sleep disorders, including narcolepsy, with these stable formulations of GHB. The present invention also provides methods to treat alcohol and opiate withdrawal, reduced levels of growth hormone, increased intracranial pressure, and physical pain in a patient.

Disclosed are implantable or insertable medical devices that provide resistance to microbial growth on and in the environment of the device and resistance to microbial adhesion and biofilm formation on the device. In particular, the invention discloses implantable or insertable medical devices that comprise at least one biocompatible matrix polymer region, an antimicrobial agent for providing resistance to microbial growth and a microbial adhesion / biofilm synthesis inhibitor for inhibiting the attachment of microbes and the synthesis and accumulation of biofilm on the surface of the medical device. Also disclosed are methods of manufacturing such devices under conditions that substantially prevent preferential partitioning of any of said bioactive agents to a surface of the biocompatible matrix polymer and substantially prevent chemical modification of said bioactive agents

The present invention relates to compositions including peroxyacetic acid and peroxyoctanoic acid and methods for preventing microbial growth in aqueous streams including the step of applying a composition of the invention to the stream. The compositions and methods can control microbial growth in aqueous streams used for transporting or processing food products.

A fire protection system includes a dry pipe system and a controlled discharge gas vent. The dry pipe system and controlled discharge gas vent operate using a breathing cycle to displace oxygen and / or water vapor from within the piping network of the dry pipe system. The controlled gas discharge vent allows displacement of pressurized air with nitrogen, for example, using manual or automated processes that can employ one or more sensors. Corrosion resulting from oxygen, water, and / or microbial growth is reduced or nearly eliminated.

Systems and methods for microorganism growth are disclosed. The systems include continuous-culture processes for the growth of large volumes of microorganisms.

Synergistic mixtures of biocides and their use to control the growth of microorganisms in aqueous systems are disclosed. The method of using the synergistic mixtures entails adding an effective amount of a nitrogenous compound activated by an oxidant and at least one non-oxidizing biocide to an aqueous system. The amount of activated nitrogenous compound and non-oxidizing biocide is selected to result in a synergistic biocidal effect.

The invention comprises a composite microbial agent applicable to efficiency enhancement of common chemical industry sewage treatment systems. The composite microbial agent applicable to efficiency enhancement of the common chemical industry sewage treatment systems meets the demands on treatment on comment pollutants in existing chemical industry and environmental production as well as on establishment of functional bacteria required by a stable bacteria flora. According to one of the schemes, the composite microbial agent is composed of 108 microorganisms of three major functional types. When the composite microbial agent is added together with microbial growth promoting carriers, nutrient agents and the like into a biochemical system, the composite microbial agent can promote establishment of a complete food chain in the biochemical system through various microorganisms with special pollutant degrading capabilities and comprehensive metabolic manners to enhance utilization and metabolic decomposition of pollutants in sewage through the microorganisms, thereby achieving efficient reduction of COD (chemical oxygen demand), ammonia nitrogen, phosphorous, sulfur and like.